Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIR2501 in prevention or reduction of paclitaxel-induced peripheral neuropathy
CTR20254498Phase 2Active
- Sponsor
- Vitality Biopharma, Inc.
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of SIR2501 in chemotherapy-induced peripheral neuropathy (CIPN), sponsored by Vitality Biopharma, Inc.. Started Nov 2025; status: active.
02
Drugs
SIR2501
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on CTR20254498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254498.